TrialClinical pharmacokinetics2021

Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.

Joseph Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.